Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 18.0% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,143,093 shares of the biopharmaceutical company's stock after acquiring an additional 174,056 shares during the period. Goldman Sachs Group Inc. owned 1.05% of Regeneron Pharmaceuticals worth $724,984,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC grew its stake in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 686 shares during the period. American Assets Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $427,000. Envestnet Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 12.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 91,138 shares of the biopharmaceutical company's stock worth $64,921,000 after acquiring an additional 10,060 shares during the period. Federated Hermes Inc. increased its stake in Regeneron Pharmaceuticals by 535.5% during the fourth quarter. Federated Hermes Inc. now owns 35,963 shares of the biopharmaceutical company's stock worth $25,618,000 after acquiring an additional 30,304 shares during the last quarter. Finally, Cerity Partners LLC raised its position in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Cerity Partners LLC now owns 16,060 shares of the biopharmaceutical company's stock valued at $12,576,000 after purchasing an additional 512 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Down 2.6%

Shares of NASDAQ REGN opened at $555.13 on Thursday. The business has a 50-day moving average of $536.31 and a two-hundred day moving average of $601.45. The company has a market capitalization of $59.93 billion, a price-to-earnings ratio of 13.99, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company posted $11.56 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research analyst reports. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a report on Monday. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Finally, Citigroup reiterated a "buy" rating and issued a $650.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $841.30.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.